Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a PARP inhibitor.
FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer

September 27th 2023

The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a PARP inhibitor.

Gilead Discontinues Phase 3 ENHANCE-2 Trial | Image Credit: ©freshidea - stock.adobe.com
Gilead Discontinues Phase 3 ENHANCE-2 Trial of Magrolimab Plus Azacitidine in TP53-Mutant AML

September 27th 2023

FDA
ABM-1310 Receives FDA Fast Track Designation for BRAF V600E+ Glioblastoma

September 26th 2023

Newly Diagnosed FLT3 ITD+ AML |   Image Credit: © Rubbina - stock.adobe.com
CHMP Releases Positive Opinion for Quizartinib in Newly Diagnosed FLT3-ITD+ AML

September 15th 2023

Colorectal Cancer ©  stock.adobe.com
Novel mRNA Biomarker Integration Boosts Sensitivity, Specificity of ColoAlert in Detecting CRC

September 13th 2023

Video Series
Video Interviews
Podcasts

More News